Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia

Holler, C, Zaborsky, N, Hofbauer, JP, Kocher, T, Trapin, D, Asslaber, D, Greil, R, Egle, A BLOOD. 2011, 118(21): 365-365.

CLL CELLS INDUCE CLONAL T CELL SKEWING AND SUBSETSHIFTING IN THE MURINE TCL1 TRANSGENIC CHRONIC LYMPHOCYTIC LEUKEMIA MODEL

Egle, A, Pinon-Hofbauer, J, Heyder, C, Denk, U, Kocher, T, Holler, C, Trapin, D, Asslaber, D, Tinhofer, I, Greil, R ANN ONCOL. 2011, 22: 144-144.

Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia

Wacht, N, Sifft, E, Melchardt, T, Hamacher, F, Denk, U, Pinon-Hofbauer, J, Egle, A, Kocher, T, Steurer, M, Greil, R, Merkel, O ONKOLOGIE. 2011, 34: 141-141.

Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study

Gisslinger, H, Kralovics, R, Schoder, R, Gisslinger, B, Buxhofer-Ausch, V, Strecker, K, Wolf, D, Willenbacher, E, Greil, R, Egle, A, Melchardt, T, Burgstaller, S, Tarmann, FJ, Wachter, C, Zahriycick, O, Thaler, J BLOOD. 2011, 118(21): 762-762.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R Lancet Oncol. 2011 Jul,12(7):631-41. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5.

Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).

Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J. Anticancer Res. 2011 Dec,31(12):4439-43.

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP. J Neurooncol. 2011 Dec,105(3):613-20. doi: 10.1007/s11060-011-0629-y. Epub 2011 Jun 26.

Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.

Grundbichler M, Mlineritsch B, Ressler S, Moik M, Kappacher A, Rosenlechner S, Greil R. Oncology. 2011,80(1-2):34-41. doi: 10.1159/000328086. Epub 2011 May 23.

Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M. J Clin Oncol. 2011 Jul 1,29(19):2653-9. doi: 10.1200/JCO.2010.33.2585. Epub 2011 May 9.

Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.

Greil R, BorГ…ВЎtnar S, PetrГЎkovГЎ K, Marcou Y, Pikiel J, Wojtukiewicz MZ, Koza I, Steger GG, Linn M, Das Gupta A, Cwiertka K. Onkologie. 2011,34(5):233-8. doi: 10.1159/000327710. Epub 2011 Apr 26.